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For many years rising antibiotic resistance of bacterial patho-
gens has been observed in both the Gram-positive and Gram-
negative bacteria. In fact, introducing chloroquine into treat-
ment of malaria more than 60 years ago triggered a new era
of rapidly developing antimicrobial drugs. To improve the
potency and antibacterial spectrum of existing drugs, many
research groups have been put considerable efforts in this area
(Sreeramulu et al., 2011; Salman et al., 2015; Sreeramulu and
Ashokgajapathiraju, 2014; Bukvic et al., 2009). A key goal,
however, is that of finding new chemical entries rather than
enduring the search for new member of previously defined
chemical classes (Xu et al., 2009; Kabir et al., 2008;
Hirokawa et al., 2008; Aridoss et al., 2008). The nitrogen-
containing heterocycles have always constituted a subject of
immense interest due to their ubiquity in nature and well-
known presence as a part of skeletal backbone of several ther-
apeutic agents. Some of the indole based entities (SaundanePlease cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
dihydropyrazino[1,2-a]indol-1(2H)-one derivatives. Arabian Journal of Chemistry (2et al., 2013; Paudel et al., 2012; Yang et al., 2012;
Youngsaye et al., 2012; Jiang et al., 2012; El-Sayed et al.,
2011; Zoraghi et al., 2011; Kamaria et al., 2011; Tomkiewicz
et al., 2010; Damodiran et al., 2009; Samsoniya et al., 2009;
Wang et al., 2000; Cirrincione et al., 1999; Hishmat et al.,
1988) are reported for their antimicrobial activities. Moreover,
in synthetic medicinal chemistry the pyrazino[1,2-a]indoles
motif is widely exploited revealing a spectrum of important
biological activities such as serotonin antagonist (Ruppelt
et al., 1999), thrombolytic (McCort et al., 1998) in cardiovas-
cular diseases (McCort et al., 1998), antidepressant, anxiolytic
(Commons et al., 1996), central nervous system depressants
(Freed, 1977), anticonvulsants (Mokrosz et al., 1994), antihis-
taminic (Basanagoudar et al., 1991; Rajur et al., 1989), protein
kinase C inhibitors (Davis et al., 1991; Bit et al., 1993), 5-HT2A
(Fong et al., 2002), 5-HT2C (Fong et al., 2002; Bos et al., 1997)
and selective imidazoline I2 receptor ligands (Glennon et al.,
2004) and have been paid significant attention. Recently, the
chemical entities containing pyrazino[1,2-a] indole nucleusion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
015), http://dx.doi.org/10.1016/j.arabjc.2015.08.034
Novel urea, sulfonamide and acetamide 3,4-dihydropyrazino[1,2-a]indol-1(2H)-one derivatives 3were identified as a novel potent antiproliferative agent against
the human chronic myelogenous leukemia K562 cell line
(Romagnoli et al., 2009).
On the other hand, literature survey revealed that some of
the substituted 10-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]in-
doles have possessed antifungal and antibacterial activities
(Tiwari et al., 2006a, 2006b). Due to the exceeding biological
importance of pyrazino[1,2-a]indoles nucleus, we aimed to
examine new representatives of these tricyclic ring system
based on a functionalized 3,4-dihydropyrazino[1,2-a]indol-1
(2H)-one scaffold. The structures of synthesized compoundsScheme 1 Synthetic scheme for
Scheme 2 Synthetic scheme for the t
Please cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
dihydropyrazino[1,2-a]indol-1(2H)-one derivatives. Arabian Journal of Chemistry (2were assigned on the basis of 1H NMR and 13C NMR data.
These compounds were evaluated for their antimicrobial
screening on different strains of bacteria and fungi.2. Chemistry
The synthetic route of compounds (4a–e), (7a–f), (9a–d) and
(12a–d) is shown in Schemes 1–3 respectively.
The starting material ethyl 1-(2-bromoethyl)-1H-indole-2-
carboxylate 2 was obtained by the coupling reaction of ethylthe title compounds (4a–e).
itle compounds (7a–f) and (9a–d).
ion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
015), http://dx.doi.org/10.1016/j.arabjc.2015.08.034
Scheme 3 Synthetic scheme for the title compounds (12a–d).
4 R.B. Toche, R.A. Janrao1H-indole-2-carboxylate 1 with 1,2-dibromoethane in the pres-
ence of K2CO3 as a base and acetonitrile as a solvent (Tapia
et al., 2002). Subsequently, the cyclization reaction of ethyl
1-(2-bromoethyl)-1H-indole-2-carboxylate 2 and equimolar
amounts of amines (3a–e) in acetonitrile provided 2-(substitu
ted)-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one (4a–e) respec-
tively (Scheme 1).
The novel cyclized key intermediate 2-amino-3,4-
dihydropyrazino[1,2-a]indol-1(2H)-one 5 was achieved by
cyclocondensation reaction of hydrazine monohydrate with
compound 2 at 80 C. Further the compound 5 was used as
key intermediate for the synthesis of compounds (7a–f), (9a–
d) and (12a–d) respectively. So the 1-(aryl)-3-(1-oxo-3,4-dihy
dropyrazino[1,2-a]indol-1(2H)-yl)urea (7a–f) were synthesized
by nucleophilic addition of compound 5 to equimolar amounts
of aryl isocynates (6a–f) in dichloromethane at room tempera-
ture. Furthermore, the various (substituted)-N-(1-oxo-3,4-
dihydropyrazino[1,2-a]indol-1(2H)-yl)aryl sulfonamide (9a–d)
were synthesized by nucleophilic substitution reaction of aryl
sulfonyl chlorides (8a–d) with compound 5 in the presence of
pyridine as a base and dichloromethane as solvent at room
temperature (Scheme 2).
On the other hand, the 2-(substituted)-N-(3,4-dihydro-1-
oxopyrazino[1,2-a]indol-1(2H)-yl)acetamide (12a–d) were
achieved via two step synthesis. In step first, the 2-chloro-N-
(3,4-dihydro-1-oxopyrazino[1,2-a]indol-1(2H)-yl)acetamide 10
was obtained by coupling reaction of chloroacetic acid and
compound 5 by using 1-(3-dimethylaminopropyl)-3-ethylcarbo
diimide hydrochloride (EDC.HCl) in dichloromethane at
room temperature. In the second step, the equimolar amounts
of cyclic amines (11a–d) were condensed with 2-chloro-N-(3,
4-dihydro-1-oxopyrazino[1,2-a]indol-1(2H)-yl)acetamide 10
afforded 2-(substituted)-N-(3,4-dihydro-1-oxopyrazino[1,2-a]
indol-1(2H)-yl)acetamide (12a–d).
3. Results and discussion
3.1. Analytical results
A series of four allied candidates (4a–e), (7a–f), (9a–d) and
(12a–d) were synthesized substantially through the syntheticPlease cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
dihydropyrazino[1,2-a]indol-1(2H)-one derivatives. Arabian Journal of Chemistry (2route as illustrated in Schemes 1–3. The off structure reaction
products were confirmed by means of 1H NMR and 13C NMR
spectra, e.g. 1H NMR spectrum of compound 2 indicated the
presence of two triplet signals appeared at d 4.97–4.93 ppm
and d 3.82–3.76 ppm of adjoining CH2 protons of bromoethyl
group. The 13C NMR spectra exhibited highest frequency sig-
nal at d 165.78 ppm assignable to ester carbonyl, where as sig-
nals appeared around d 31.71 and 52.84 ppm were assigned for
two CH2 of bromethyl carbons. Furthermore, the
1H NMR
spectrum of compound (4a–e) showed singlet for methylene
proton at d 4.74 ppm and aromatic protons resonate as multi-
plets at d 6.90–7.68 ppm. The 13C NMR spectrum is in well
agreement with the structure assigned. In the 13C NMR spec-
tra, signals appeared around d 43.18–48.64 ppm are assigned
for methylene carbons whereas d 121.13–136.76 ppm is attrib-
uted to aromatic carbons and carbonyl carbon was observed at
about d 159.20 ppm. The key intermediate 5 (Katritzky et al.,
2003) was characterized by 1H NMR spectrum which exhibited
lack of the characteristic signal as quartet triplet pattern corre-
sponding to the ethyl ester of compound 2 and the presence of
broad singlet at d 5.18 ppm NH2 group (D2O exchangeable).
13C NMR spectra exhibited highest frequency signal at d
158.14 ppm assignable to the pyrazino carbonyl carbon,
whereas lowest frequency signal appears between 45.01 and
50.86 ppm for two CH2 carbons of newly formed 3,4-
dihydropyrazino ring in all the spectra. The 1H NMR spectra
of urea derivatives (7a–f) indicated the presence of two broad
singlets appeared at around d 9.54 ppm for NH proton
attached to the pyrazino ring whereas other NH proton
attached to aryl ring appeared at around d 8.72 ppm. More-
over, disappearance of broad singlet at d 5.18 ppm of NH2
proton of compound 5 clearly confirmed the formation of urea
derivatives. In 13C NMR spectra of urea derivatives the most
characteristic signal appears at d 160.54 ppm for the carbonyl
carbon between two NH groups of urea. Furthermore, the 1H
NMR spectrum of sulfonamide derivatives (9a–d) showed
addition of aromatic multiplet and most downfield broad
singlet appeared at around d 10.05–11.02 ppm for sulfonamide
NH proton. 13C NMR spectra showed highest frequency
signal range observed around d 158.67 ppm assignable to the
pyrazino carbonyl carbon. Finally, the 1H NMR spectrum ofion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
015), http://dx.doi.org/10.1016/j.arabjc.2015.08.034
Novel urea, sulfonamide and acetamide 3,4-dihydropyrazino[1,2-a]indol-1(2H)-one derivatives 5acetamide derivatives (12a–d) showed one downfield broad
singlet signal appears at around d 10.24 ppm corresponding
to NH protons, whereas sharp singlet of amidic CH2 protons
observed at d 3.08 ppm. 13C NMR revealed the highest fre-
quency signals at d 168.83 ppm assigned for carbonyl carbon
of amide function.
3.2. Antimicrobial activity results
The results of antimicrobial screening of newly prepared com-
pounds were expressed as the MIC values are summarized in
Table 1.
Many of newly synthesized compounds are found to exhibit
good to excellent antimicrobial activity. From antimicrobial
activity data (Tables 1 and 2), it is observed that compounds
4b (R = 4-Cl–C6H4), 7b (R = Cl), 9d (R = 3,4-di-Cl–C6H3),
4e (R = morpholine) and 12b (R1, R2 = morpholine) are most
active compounds. Data of antibacterial activity reveal that,
compounds 4b (R = 4-Cl–C6H5), 7f (R = –COOMe), 9a
(quinoline-8-sulfonamide) and 9d (R = 3,4-di-Cl–C6H3), are
considered to be good active against Escherichia coli. When
we have taken the morpholine group as substitution in com-
pounds 4e and 12b, it shows excellent activity against E. coli.
Compounds 4b (R = 4-Cl–C6H4), 7b (R = Cl), 7f
(R = COOMe) and 9d (R = 3,4-di-Cl–C6H3) are considered
as good active against Pseudomonas aeruginosa, while com-Table 1 Results of antibacterial screening of compounds 4a–e, 7a–
N
N
O
H
N HN
O
R(7a-f)
N
N
O
R
(4a-e)
Minimum Inhibitory Concentration (MIC) for bacteria (lg/mL)
Compound numbers Gram-negative
E.C. MTCC 443 P.A. MTCC
4a 200 200
4b 100 100
4c 125 125
4d 500 250
4e 62.5 50
7a 200 200
7b 200 100
7c 125 200
7d 200 250
7e 200 125
7f 100 100
9a 100 200
9b 200 125
9c 500 200
9d 100 100
12a 250 125
12b 62.5 50
12c 500 250
12d 500 500
Ampi. 100 100
S.A., Staphylococcus aureus; S.P., Streptococcus pyogenes; E.C., Esche
Culture Collection; Ampi., Ampicillin.
Please cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
dihydropyrazino[1,2-a]indol-1(2H)-one derivatives. Arabian Journal of Chemistry (2pounds 4e (R = morpholine) and 12b (R1, R2 = morpholine)
are considered as very good active against P. aeruginosa. Com-
pounds 4b (R = 4-Cl–C6H4), 7b (R = Cl), 7c (R = OMe),
and 9d (R = 3,4-di-Cl–C6H3) are considered as good active
against Staphylococcus aureus, while compounds 4e (R = mor-
pholine), 12b (R1, R2 = morpholine) and 9a (quinoline-8-
sulfonamide) are considered as very good active against
S. aureus. Compounds 4b (R = 4-Cl–C6H4), 4e (R = morpho-
line) and 9d (R = 3,4-di-Cl–C6H3) are considered to be good
active against Streptococcus pyogenes, while compound 12b
(R1, R2 = morpholine) is considered as very good active
against S. pyogenes. For the antifungal activity, we have
screened the same compounds which are used for antibacterial
activity. Compounds 4b (R = 4-Cl–C6H4), 4e (R = morpho-
line), 9a (quinoline-8-sulfonamide), 9b (R = 4-OCF3–C6H4)
and 12a (4-methyl piperazine) are considered as good active
against Candida albicans, while compounds 4c (R = 4-
OCH3–C6H5), 7b (R = Cl), 7c (R = OCH3), 7d (R = CN),
9d (R = 3,4-di-Cl–C6H3) and 12b (R1, R2 = morpholine) are
considered as excellent active against C. albicans. Compounds
4e and 12b are considered as good active against Aspergillus
niger. Only compound 12b is good active against Aspergillus
clavatus among the entire screened compounds. We have
discussed and compared antibacterial and antifungal activi-
ties based on standard drugs ampicillin and griseofulvin,
respectively.f, 9a–d and 12a–d.
N N
O
H
N
O
(12a-d)
N
N
N
O
H
N
S
O
O R
(9a-d)
R2
R1
Gram-positive
1688 S.A. MTCC 96 S.P. MTCC 442
500 250
250 100
500 250
500 500
125 100
500 200
250 200
250 500
500 250
500 500
500 500
125 250
500 500
500 125
250 100
500 125
125 50
500 500
500 250
250 100
richia coli; P.A., Pseudomonas aeruginosa; MTCC, Microbial Type
ion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
015), http://dx.doi.org/10.1016/j.arabjc.2015.08.034
Table 2 Results of antifungal screening of compounds 4a–e,
7a–f, 9a–d and 12a–d.
Minimum Inhibitory Concentration (MIC) for fungi (lg/mL)
Compound
numbers
C.A. MTCC
227
A.N. MTCC
282
A.C. MTCC
1323
4a >1000 250 250
4b 500 250 250
4c 250 1000 1000
4d 1000 500 500
4e 500 100 250
7a >1000 >1000 >1000
7b 250 500 500
7c 250 >1000 >1000
7d 250 500 500
7e 1000 1000 1000
7f 1000 >1000 >1000
9a 500 500 500
9b 500 500 500
9c 1000 250 500
9d 250 500 500
12a 500 >1000 >1000
12b 250 100 100
12c 1000 500 500
12d 1000 500 500
Grise. 500 100 100
C.A., Candida albicans; A.N., Aspergillus niger; A.C., Aspergillus
clavatus; Grise., Griseofulvin.
6 R.B. Toche, R.A. Janrao3.3. Antimicrobial testing method
The MICs of synthesized compounds were carried out by
broth microdilution method using DMSO as diluents to get
desired concentration of compounds to test upon standard
bacterial strains. Serial dilutions were prepared in primary
and secondary screening. The control tube containing no
antibiotic was immediately subcultured (before inoculation)
by spreading a loopful evenly over a quarter of plate of med-
ium suitable for the growth of the test organism and put for
incubation at 37 C overnight. The tubes were then incubated
overnight. The MIC of the control organism was read to check
the accuracy of the compound concentrations. The MIC was
defined as the lowest concentration of the antibiotic or test
sample allowing no visible growth. All the tubes showing no
visible growth (same as control tube) were subcultured and
incubated overnight at 37 C. The amount of growth from
the control tube before incubation (which represents the orig-
inal inoculum) was compared. Subcultures might show similar
number of colonies indicating bacteriostatic, a reduced num-
ber of colonies indicating a partial or slow bactericidal activity
and no growth if the whole inoculum has been killed. The test
must include a second set of the same dilutions inoculated with
an organism of known sensitivity. Each synthesized compound
was diluted obtaining 2000 lg/mL concentration as a stock
solution. In primary screening 500, 250 and 200 lg/mL con-
centrations of the synthesized compounds were taken. The
active synthesized compounds found in this primary screening
were further tested in second set of dilution against all
microorganisms. The compounds found active in primary
screening were similarly diluted to obtain 100, 62.5, 50 and
25 lg/mL concentrations. The highest dilution showing at least
99% inhibition is taken as MIC.Please cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
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4.1. Materials and methods
All reactions were monitored by thin layer chromatography
(TLC), carried out on 0.2 mm silica gel 60 F254 (Merck) plates
using UV light (254 and 366 nm) for detection. 1H NMR and
13C NMR spectra were recorded on a Bruker spectrometer oper-
ating at 300 and 75 MHz for 1H and 13C respectively using either
CDCl3 or DMSO-d6 as the solvent. Chemical shifts, d, are
reported in parts per million (ppm) relative to solvent resonance:
CDCl3, d 7.26 (
1H NMR), and 77.3 (13C NMR); DMSO-d6, d
2.50 (1H NMR), and 40.2 (13C NMR). Multiplicities are indicated
by s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet).
Coupling constants, J, are reported in Hertz. All melting points
have been determined on a manually operated Veego (VMP-1)
melting point apparatus and are reported uncorrected.
4.2. Synthesis of ethyl 1-(2-bromoethyl)-1H-indole-2-
carboxylate (2)
A mixture of 1,2-dibromo ethane (52.0 mmol, 4.5 mL), potas-
sium carbonate (79.3 mmol, 10.9 g) and ethyl 1H-indole-2-
carboxylate 1 (26.4 mmol, 5.0 g) in of acetonitrile (50 mL)
was at reflux for 72 h. After cooling the reaction mixture the
salt was filtered out and washed with (20 mL) acetonitrile.
The residue was concentrated and purified by column chro-
matography with petroleum ether/ethyl acetate (6:1 to 3:1) as
an eluent to give as viscous oil 2: Yield 65%; m.p. 155–
158 C. 1H NMR (300 MHz, DMSO-d6) d: 7.70–7.66 (t, 2H,
J= 7.5 Hz, ArH), 7.39–7.35 (m, 1H, ArH), 7.32 (s, 1H,
indole), 7.17–7.12 (t, 1H, J= 7.8 Hz, ArH), 4.97–4.93 (t,
2H, J= 13.2 Hz), 4.36–4.29 (q, 2H, J= 6.8 Hz, ester), 3.82–
3.76 (t, 2H, J= 6.6 Hz, CH2Br), 1.36–1.31 (t, 3H,
J= 3.6 Hz, ester) ppm. 13C NMR (75 MHz, DMSO-d6) d:
13.83, 31.71, 52.84, 61.34, 103.80, 117.27, 123.12, 125.52,
127.60, 131.71, 148.34, 147.20, 165.78 ppm.
4.3. General procedure for the synthesis of 2-(substituted)-3,4-
dihydropyrazino[1,2-a]indol-1(2H)-one 4a–e
To a solution of ethyl 1-(2-bromoethyl)-1H-indole-2-
carboxylate 2 (0.100 g, 0.169 mmol) in acetonitrile (10 mL) at
room temperature appropriate amines (3a–e) (0.186 mmol)
was added. The mixture was heated at 80 C for 20 min. After
cooling the reaction mixture was quenched with cold water.
The formed solid was filtered and washed with water to give
pure compound 4a–e respectively.
4.3.1. 2-Benzyl-3,4-dihydropyrazino[1,2-a]indol-1(2H)-one (4a)
White solid, (0.063 g), Yield, 68%; m.p. 130–132 C, 1H NMR
(300MHz, DMSO-d6) d: 7.70–7.67 (d, 1H, J=8.1 Hz, ArH),
7.54–7.51 (d, 1H, J=8.4 Hz, ArH), 7.44–7.39 (m, 5H, ArH),
7.33–7.28 (t, 1H, J=7.8 Hz, ArH), 7.14 (s, 1H, indole CH),
7.11–7.09 (d, 1H, J=5.1 Hz), 4.74 (s, 2H, benzylic CH2), 4.36–
4.32 (t, 2H, J= 5.7 Hz, NCH2CH2N), 3.78–3.74 (t, 2H,
J= 6.0 Hz, NCH2CH2N) ppm.
13C NMR (75MHz, DMSO-
d6) d: 45.02, 51.73, 106.60, 111.31, 113.91, 115.90, 116.18,
121.13, 122.69, 125.23, 126.23, 127.03, 128.44, 130.78, 136.76,
158.61 ppm. LC–MS: (277.3, 96.76%)ion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
015), http://dx.doi.org/10.1016/j.arabjc.2015.08.034
Novel urea, sulfonamide and acetamide 3,4-dihydropyrazino[1,2-a]indol-1(2H)-one derivatives 74.3.2. 2-(4-Chlorobenzyl)-3,4-dihydropyrazino[1,2-a]indol-1
(2H)-one (4b)
White solid, Yield: 0.077 g, 74%; m.p. 202–204 C. 1H NMR
(300 MHz, DMSO-d6) d: 7.70–7.67 (d, 1H, J= 7.8 Hz, ArH),
7.53–7.51 (d, 1H, J= 8.4 Hz), 7.39–7.27 (m, 5H, ArH), 7.14
(s, 1H, indole CH), 7.11–7.09 (d, 1H, J= 5.7 Hz, ArH), 4.75
(s, 2H, CH2), 4.35–4.32 (t, 2H, J= 5.7 Hz, NCH2CH2N),
3.77–3.73 (t, 2H, J= 6.0 Hz, NCH2CH2N) ppm.
13C NMR
(75 MHz, DMSO-d6) d: 46.01, 48.74, 105.22, 111.14, 120.87,
122.50, 124.52, 127.17, 129.04, 129.04, 129.73, 129.73, 130.14,
132.36, 136.61, 136.91, 159.56 ppm. LC–MS: (311.1, 97.50%).
4.3.3. 2-(4-Methoxybenzyl)-3,4-dihydropyrazino[1,2-a]indol-1
(2H)-one (4c)
Off white solid: Yield, 0.079 g, 77%; m.p. 177–180 C. 1H NMR
(300 MHz, DMSO-d6) d: 7.69–7.66 (d, 1H, J= 7.8 Hz, ArH),
7.52–7.49 (d, 1H, J= 8.4 Hz, ArH), 7.31–7.27 (m, 3H, ArH),
7.13 (s, 1H, ArH, indole CH), 7.11–7.08 (t, 1H, J= 3.9 Hz,
ArH), 6.93–6.90 (d, 2H, J= 8.4 Hz, ArH), 4.67 (s, 2H, ben-
zylCH2), 4.23–4.28 (t, 2H, J= 5.4 Hz, NCH2CH2N), 3.73 (s,
3H, OCH3), 3.70–3.68 (t, 2H, J= 5.7 Hz, NCH2CH2N) ppm.
13C NMR (75 MHz, DMSO-d6) d: 45.62, 48.64, 55.52, 105.05,
111.09, 114.45, 120.81, 122.44, 124.41, 127.16, 129.69, 129.90,
136.54, 159.03 ppm. LC–MS: (301.3, 97.53%).
4.3.4. 2-((Naphthalen-1-yl)methyl)-3,4-dihydro-pyrazino[1,2-
a]indol-1(2H)-one (4d)
White solid: Yield, 0.076 g, 69%; m.p. 186–189 C. 1H NMR
(300 MHz, DMSO-d6) d: 8.22–8.19 (d, 1H, J= 8.4 Hz,
ArH), 7.99–7.91 (dd, 2H, J= 7.2 Hz, ArH), 7.71–7.69 (d,
1H, J= 8.1 Hz, ArH), 7.58–7.48 (m, 5H), 7.32–7.27 (t, 1H,
J= 7.2 Hz, ArH), 7.17 (s, 1H, indole CH), 7.15–7.10 (t, 1H,
J= 7.5 Hz, ArH), 5.23 (s, 2H, benzyl CH2), 4.27–4.25 (t,
2H, J= 5.4 Hz, NCH2CH2N), 3.74–3.71 (t, 2H, J= 5.7 Hz,
NCH2CH2N) ppm.
13C NMR (75 MHz, DMSO-d6) d: 45.38,
47.08, 105.36, 111.14, 120.90, 122.51, 123.99, 124.53, 126.00,
127.01, 127.21, 128.67, 129.16, 131.59, 132.87, 133.99, 136.59,
159.35 ppm. LC–MS: (327.2, 97.25%).
4.3.5. 2-(2-Morpholinoethyl)-3,4-dihydro-pyrazino[1,2-a]
indol-1(2H)-one (4e)
White solid: Yield, 0.075 g, 75%; m.p. 161–163 C. 1H NMR
(300 MHz, DMSO-d6) d: 7.68–7.65 (d, 1H, J= 8.1 Hz, ArH),
7.55–7.52 (d, 1H, J= 8.4 Hz, ArH), 7.32–7.27 (t, 1H,
J= 8.1 Hz, ArH), 7.13–7.08 (t, 1H, J= 7.8 Hz, ArH), 7.03 (s,
1H, indole CH), 4.35–4.31 (t, 2H, J= 5.4 Hz, ArH), 3.88–3.84
(t, 2H, J= 6.0 Hz, morpholin CH2), 3.66–3.62 (t, 2H,
J= 6.3 Hz, NCH2CH2N), 3.56–3.53 (t, 4H, J= 4.5 Hz, NCH2-
CH2N), 2.55–2.51 (m, 2H, morpholin CH2), 2.49–2.43 (m, 2H,
morpholin CH2) ppm.
13C NMR (75 MHz, DMSO-d6) d:
43.18, 46.58, 53.80, 53.80, 56.20, 66.77, 66.77, 104.64, 111.10,
120.76, 122.40, 124.29, 127.15, 130.11, 136.46, 159.20 ppm.
LC–MS: (300.2, 99%).
4.4. Synthesis of 2-amino-3,4-dihydropyrazino[1,2-a]indol-1
(2H)-one (5)
Mixture of hydrazine monohydrate (1.69 mmol, 0.084 g) and
compound 2 (0.169 mmol, 0.050 g) was heated at 80 C for
30 min (TLC check). After cooling the reaction mixture toPlease cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
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washed with excess of water to get colorless solid; Yield,
0.042 g, 75%; m.p. 234–238 C. 1H NMR (300 MHz,
DMSO-d6) d: 7.68–7.65 (d, 1H, J= 8.1 Hz, ArH), 7.54–7.51
(d, 1H, J= 8.1 Hz, ArH), 7.32–7.27 (m, 1H, ArH),7.31–7.08
(m, 1H, ArH), 7.04 (s, 1H, indole CH), 5.18 (br.s, 2H, NH2,
D2O-exchangable), 4.40–4.38 (t, 2H, J= 6.0 Hz, NCH2CH2N),
3.91–3.87 (t, 2H, J= 6.3 Hz, NCH2CH2N) ppm.
13C NMR
(75 MHz, DMSO-d6) d: 49.74, 104.46, 111.05, 120.77, 122.38,
124.35, 127.39, 129.87, 136.63, 158.64 ppm. LC–MS: (202.2,
94.95%).
4.5. General procedure for the synthesis of 1-(aryl)-3-(1-Oxo-
3,4-dihydropyrazino[1,2-a]indol-1(2H)-yl)urea 7a–f
To a solution of compound 5 (0.100 g, 0.248 mmol) in dry
dichloromethane (10 mL) at room temperature was added
the substituted aromatic isocyanates (6a–f) (0.273 mmol).
The reaction mixture was stirred at room temperature overnight.
The obtained solid was filtered and washed with 10 mL of
chloroform to get pure product.
4.5.1. 1-(Phenyl)-3-(1-oxo-3,4-dihydropyrazino[1,2-a]indol-1
(2H)-yl)urea (7a)
White solid: Yield 0.119 g, 75%; m.p 167–169 C. 1H NMR
(300 MHz, DMSO-d6) d: 9.00 (br.s, 1H, aromatic NH), 8.62
(br.s, 1H, pyrazino NH), 7.72–7.69 (d, 1H, J= 8.1 Hz,
ArH), 7.59–7.56 (d, 1H, J= 8.7 Hz), 7.49–7.47 (d, 2H,
J= 7.5 Hz, ArH), 7.37–7.32 (t, 1H, J= 7.5 Hz, ArH), 7.29–
7.24 (t, 1H, J= 7.5 Hz, ArH), 7.17–7.12 (m, 2H, ArH),
7.00–6.98 (m, 2H, ArH), 4.50–4.53 (t, 2H, J= 5.3 Hz, NCH2-
CH2N), 4.04–3.98 (t, 2H, J= 5.1 Hz, NCH2CH2N) ppm.
13C
NMR (75 MHz, DMSO-d6) d: 50.94, 105.93, 111.29, 119.10,
120.98, 122.61, 122.61, 122.61, 124.89, 127.19, 129.13, 129.13,
129.13, 129.71, 136.74, 139.88, 155.23, 160.14 ppm. LC–MS:
(321.2, 97.54%).
4.5.2. 1-(4-Chlorophenyl)-3-(1-oxo-3,4-dihydropyrazino[1,2-a]
indol-1(2H)-yl)urea (7b)
White solid: Yield, 0.125 g, 71.5%; m.p. 197–199 C. 1H NMR
(300 MHz, DMSO-d6) d: 9.15 (br.s, 1H, aromatic NH) 8.72
(br.s, 1H, Pyrazino NH), 7.72–7.69 (d, 1H, J= 8.1 Hz,
ArH), 7.59–7.51 (m, 3H, ArH), 7.37–7.30 (m, 3H, ArH), 7.17
(s, 1H, indole CH), 7.14–7.03 (m, 1H, ArH), 4.52–4.49 (t,
2H, J= 5.4 Hz, NCH2CH2N), 4.05–4.01 (t, 2H, J= 6.0 Hz,
NCH2CH2N) ppm.
13C NMR (75 MHz, DMSO-d6) d: 50.90,
105.98, 111.29, 120.68, 121.00, 122.62, 124.92, 126.15, 127.18,
128.97, 128.97, 128.97, 129.67, 136.74, 138.94, 155.13,
160.19 ppm. LC–MS: (355.2, 93.12%).
4.5.3. 1-(4-Methoxyphenyl)-3-(1-oxo-3,4-dihydropyrazino[1,2-
a]indol-1(2H)-yl)urea (7c)
White solid: Yield, 0.125 g, 72%; m.p. 245–248 C. 1H NMR
(300 MHz, DMSO-d6) d: 8.82 (br.s, 1H, aromatic NH), 8.53
(br.s, 1H, pyrazino NH), 7.72–7.69 (d, 1H, J= 7.8 Hz,
ArH), 7.59–7.56 (d, 1H, J= 8.4 Hz, ArH), 7.39–7.35 (m,
3H, ArH), 7.16 (s, 1H, indole CH), 7.14–7.15 (m, 1H, ArH),
6.87–6.84 (d, 2H, J= 9.0 Hz, ArH), 4.52–4.48 (t, 2H,
J= 5.7 Hz, NCH2CH2N), 4.05–4.01 (t, 2H, J= 5.7 Hz,
NCH2CH2N), 3.71 (s, 3H, OCH3) ppm.
13C NMR (75 MHz,ion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
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120.96, 120.96, 122.60, 124.87, 127.19, 129.76, 132.85, 136.72,
155.09, 155.43, 160.19 ppm. LC–MS: (351.2, 99.9%).
4.5.4. 1-(4-Cyanophenyl)-3-(1-oxo-3,4-dihydropyrazino[1,2-a]
indol-1(2H)-yl)urea (7d)
White solid: Yield, 0.120 g, 70%; m.p. 241–243 C. 1H NMR
(300 MHz, DMSO-d6) d: 9.54 (br.s, 1H, aromatic NH), 8.92
(br.s, 1H, pyrazino NH), 7.75–7.67 (m, 5H, ArH), 7.59–7.57
(d, 1H, J= 8.1 Hz), 7.37–7.32 (t, 1H, J= 7.2 Hz, ArH),
7.18 (s, 1H, indole CH), 7.14–7.12 (d, 1H, J= 7.5 Hz, ArH),
4.53–4.51 (t, 2H, J= 5.7 Hz, NCH2CH2N), 4.06–4.02 (t, 2H,
J= 6.0 Hz, NCH2CH2N) ppm.
13C NMR (75 MHz,
DMSO-d6) d: 50.82, 50.82, 104.10, 106.10, 111.31, 118.93,
119.71, 121.02, 122.64, 124.97, 127.17, 129.55, 133.65, 133.65,
133.35, 136.76, 144.48, 154.79, 160.11 ppm. LC–MS: (346.3,
98%).
4.5.5. 1-(4-(Trifluoromethyl)phenyl)-3-(3,4-dihydro-1-
oxopyrazino[1,2-a]indol-1(2H)-yl)urea (7e)
Off white solid: Yield, 0.129 g, 67%; m.p. 282–285 C. 1H
NMR (300 MHz, DMSO-d6) d: 9.44 (br.s, 1H, aromatic
NH), 8.85 (br.s, 1H, pyrazino NH), 7.73–7.70 (m, 3H, ArH),
7.65–7.62 (d, 2H, J= 9.0 Hz, ArH), 7.59–7.56 (d, 1H,
J= 8.4 Hz, ArH), 7.37–732 (t, 1H, J= 7.5 Hz, ArH), 7.18
(s, 1H, indole CH), 7.17–7.12 (t, 1H, J= 7.5 Hz, ArH),
4.53–4.49 (t, 2H, J= 5.7 Hz, NCH2CH2N), 4.07–4.03 (t, 2H,
J= 6.0 Hz, ArH, NCH2CH2N) ppm.
13C NMR (75 MHz,
DMSO-d6) d: 50.86, 50.86, 106.05, 111.31, 118.78, 121.01,
122.33, 122.64, 122.73, 123.20, 124.95, 126.43, 126.80, 127.17,
129.60, 136.76, 143.72, 154.98, 160.15 ppm. LC–MS: (389.1,
96.25%).
4.5.6. Methyl 4-(3-(1-Oxo-3,4-dihydropyrazino[1,2-a]indol-1
(2H)-yl)ureido)benzoate (7f)
White crystals: Yield, 0.131 g, 70%; m.p. 278–280 C. 1H
NMR (300 MHz, DMSO-d6) d: 9.43 (br.s, 1H, aromatic
NH), 8.83 (br.s, 1H, pyrazino NH), 7.90–7.87 (d, 2H,
J= 8.4 Hz, ArH), 7.72–7.57 (m, 4H, ArH), 7.38–7.33 (t, 1H,
J= 7.2 Hz, ArH), 7.18 (s, 1H, indole CH), 7.14–7.12 (d, 1H,
J= 7.2 Hz, ArH), 4.51–4.49 (t, 2H, J= 5.7 Hz, NCH2
CH2N), 4.06–4.04 (t, 2H, J= 5.7 Hz, NCH2CH2N), 3.81
(s, 3H, COOCH3) ppm.
13C NMR (75 MHz, DMSO-d6)
d: 50.85, 50.25, 106.05, 111.31, 118.25, 121.01, 122.63,
123.23, 124.95, 127.17, 129.59, 130.74, 130.74, 136.75, 144.89,
154.89, 166.57 ppm. LC–MS: (379.3, 96.76%).
4.6. General procedure for the synthesis of substituted-N-(1-
oxo-3,4-dihydropyrazino[1,2-a]indol-1(2H)-yl)aryl
sulfonamide 9a–d
To a solution of compound 5 (0.100 g, 0.248 mmol) in dichlor-
omethane (10 mL) at room temperature was added appropri-
ate aromatic sulfonyl chloride 8a–d (0.248 mmol) and
pyridine (0.497 mmol). The reaction mixture was stirred at
room temperature for 4–5 h and then diluted with water
(25 mL). The product was extracted with dichloromethane
(3  20 mL); the extract was washed with dilute citric acid
(20 mL, pH = 7.8). The organic layer was dried over sodiumPlease cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
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compound.
4.6.1. N-(1-oxo-3,4-dihydropyrazino[1,2-a]indol-1(2H)-yl)
quinoline-8-sulfonamide (9a)
Off white solid: Yield, 0.128 g, 66%; m.p. 210–212 C. 1H
NMR (300 MHz, DMSO-d6) d: 10.05 (br.s, 1H, sulfonamide
NH), 9.09–9.07 (dd, 1H, J= 1.5 Hz, ArH), 8.59–8.55 (dd, 1H,
J= 1.8 Hz), 8.33–7.71 (m, 3H, ArH), 7.69–7.67 (m, 1H, ArH),
7.60–7.57 (d, 1H, J= 8.1 Hz), 7.53–7.50 (d, 1H, J= 8.4 Hz),
7.34–7.29 (m, 1H, ArH), 7.14–7.06 (m, 1H, ArH), 6.86 (s, 1H,
indole CH), 4.47–4.41 (t, 2H, J= 6.3 Hz, NCH2CH2N),
4.14–4.10 (t, 2H, J= 6.0 Hz, NCH2CH2N) ppm.
13C NMR
(75 MHz, DMSO-d6) d: 52.16, 52.16, 106.45, 111.28, 121.06,
122.59, 122.99, 125.15, 125.90, 126.95, 128.91, 130.82, 134.76,
136.66, 136.80, 137.41, 143.81, 143.81, 151.63, 158.78 ppm.
LC–MS: (393.2, 97.19%).
4.6.2. 4-(Trifluoromethoxy-N-(1-oxo-3,4-dihydropyrazino[1,2-
a]indol-1(2H)-yl)benzene sulfonamide (9b)
White solid: Yield, 0.164 g, 81%; m.p. 233–238 C. 1H NMR
(300 MHz, DMSO-d6) d: 11.01 (br.s, 1H, sulfonamide NH),
7.95–7.92 (d, 2H, J=8.4 Hz, ArH), 7.81–7.78 (d, 1H,
J=8.1 Hz, ArH), 7.71–7.68 (d, 1H, J=8.1 Hz, ArH), 7.66–7.63
(d, 1H, J= 7.3 Hz, ArH), 7.56–7.54 (d, 1H, J= 8.1 Hz,
ArH), 7.37–7.32 (t, 1H, J= 7.5 Hz, ArH), 7.14–7.09 (t, 1H,
J= 7.8 Hz, ArH), 7.02 (s, 1H, indole CH), 4.49–4.43 (t, 2H,
J= 6.3 Hz, NCH2CH2N), 4.10–4.06 (t, 2H, J= 6.0 Hz,
NCH2CH2N) ppm.
13C NMR (75 MHz, DMSO-d6) d: 51.95,
106.68, 111.31, 121.13, 122.68, 125.28, 126.59, 126.79, 126.99,
127.50, 128.31, 129.03, 129.27, 136.77, 142.91, 143.37, 146.08,
152.63, 158.70 ppm. LC–MS: (410.1, 96.25%).
4.6.3. Fluoro-4-methoxy-N-(1-oxo-3,4-dihydropyrazino[1,2-a]
indol-1(2H)-yl) benzene sulfonamide (9c)
Colorless solid: Yield, 0.164 g, 85%; m.p. 182–184 C. 1H
NMR (300 MHz, DMSO-d6) d: 10.63 (br.s, 1H, sulfonamide
NH), 7.71–7.64 (m, 3H, ArH), 7.56–7.53 (d, 1H, J= 8.4 Hz,
ArH), 7.37–7.25 (m, 2H, ArH), 7.15–7.10 (m, 1H, ArH), 7.04
(s, 1H, indole CH), 4.49–4.46 (t, 2H, J= 5.4 Hz, NCH2CH2N),
4.07–4.4.03 (t, 2H, J= 5.1 Hz, NCH2CH2N), 3.90 (s, 3H,
OCH3) ppm.
13C NMR (75 MHz, DMSO-d6) d: 43.12, 51.90,
106.71, 111.32, 117.97, 118.26, 121.12, 122.68, 125.27, 126.99,
128.31, 129.83, 129.95, 130.79, 136.78, 158.67, 171.72,
174.97 ppm. LC–MS: (390.2, 96.25%).
4.6.4. 3,4-Dichloro-N-(1-oxo-3,4-dihydropyrazino[1,2-a]indol-
1(2H)-yl)benzene sulfonamide (9d)
Colorless solid: Yield, 0.171 g, 84%; m.p. 197–200 C. 1H
NMR (300 MHz, DMSO-d6) d: 11.02 (br.s, 1H, sulfonamide
NH), 8.08 (s, 1H, ArH), 7.86–7.77 (m, 2H, ArH), 7.66–7.64
(d, 1H, J= 8.1 Hz, ArH), 7.57–7.54 (d. 1H, J= 8.1 Hz,
ArH), 7.37–7.32 (t, 1H, J= 7.8 Hz, ArH), 7.15–7.10 (t. 1H,
J= 7.5 Hz, ArH), 7.06 (s, 1H, indole CH), 4.49–4.51 (t, 2H,
J= 5.3 Hz, NCH2CH2N), 4.10–4.08 (t, 2H, J= 5.2 Hz,
NCH2CH2N) ppm.
13C NMR (75 MHz, DMSO-d6) d: 51.97,
106.76, 111.33, 121.13, 122.69, 125.28, 126.98, 128.44, 129.90,
131.75, 132.30, 136.80, 139.75, 158.71 ppm. LC–MS: (410.1,
411.0, 412.1, 96.25%).ion and antimicrobial evaluation of novel urea, sulfonamide and acetamide 3,4-
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indol-1(2H)-yl)acetamide (10)
In compound 5 (0.994 mmol, 0.200 g) chloroacetic acid
(1.044 mmol, 0.099 g) and then 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (1.193 mmol, 0.299 g) were
added in (10 mL) of dichloromethane and the reaction mixture
was stirred for 10–15 min. The solid was filtered and washed
with water, dried and recrystallized in ethyl acetate to get white
solid, Yield, 0.198 g, 72%; m.p. 256–258 C. 1H NMR
(300 MHz, DMSO-d6) d: 10.83 (br.s, 1H, pyrazino NH),
7.72–7.69 (d, 1H, J= 8.1 Hz, ArH), 7.58–7.55 (d, 1H,
J= 8.1 Hz, ArH), 7.37–7.32 (t, 1H, J= 7.8 Hz, ArH), 7.18
(s, 1H, indole NH), 7.14–7.12 (d, 1H, J= 7.2 Hz, ArH),
4.49–4.45 (t, 2H, J= 5.7 Hz, NCH2CH2N), 4.24 (s, 2H, CH2-
Cl), 4.01–3.97 (t, 2H, J= 5.4 Hz, NCH2CH2N) ppm.
13C
NMR (75 MHz, DMSO-d6) d: 49.88, 106.34, 111.35, 121.07,
122.66, 125.05, 127.12, 129.12, 136.79, 158.85, 165.68 ppm.
LC–MS: (278.1, 98.04%).
4.8. General procedure for the synthesis of N-(3,4-dihydro-1-
oxopyrazino[1,2-a]indol-1(2H)-yl)-2-(substituted)acetamide
(12a–d)
To a solution of compound 10 (0.180 mmol) in acetonitrile
(5 mL) respective amines 11a–d (0.190 mmol) was added and
the solution stirred for 1 h in the seal vial at 80 C. Water
was added in the mixture and the solid residue was filtered
and dried to give pure 12a–d respectively.
4.8.1. N-(3,4-dihydro-1-oxopyrazino[1,2-a]indol-1(2H)-yl)-2-
(4-methylpiperazin-1-yl)acetamide (12a)
White solid: Yield, 0.096 g, 78%; m.p. 185–187 C. 1H NMR
(300 MHz, DMSO-d6) d: 10.14 (br.s, 1H, pyrazino NH),
7.71–7.68 (d, 1H, J= 8.1 Hz, ArH), 7.57–7.54 (d, 1H,
J= 8.4 Hz, ArH), 7.36–7.31 (t, 1H, J= 8.1 Hz, ArH),
7.16–7.14 (m, 1H, ArH), 7.11 (s, 1H, indole CH), 4.47–4.43
(t, 2H, J= 6.0 Hz, NCH2CH2N), 3.98–3.94 (t, 2H,
J= 5.4 Hz, NCH2CH2N), 3.08 (s, 2H, amedic CH2), 2.54–
2.50 (m, 4H), 2.40 (m, 4H), 2.18 (s, 3H, N–CH3) ppm.
13C
NMR (75 MHz, DMSO-d6) d: 46.14, 50.12, 53.08, 53.08,
54.10, 54.90, 60.34, 106.03, 111.32, 212.01, 122.61, 124.91,
127.14, 129.44, 136.74, 158.90, 168.83 ppm. LC–MS: (342.3,
98.21%).
4.8.2. N-(3,4-dihydro-1-oxopyrazino[1,2-a]indol-1(2H)-yl)-2-
morpholinoacetamide (12b)
White solid: Yield, 0.087 g, 74%; m.p. 210–212 C. 1H NMR
(300 MHz, DMSO-d6) d: 10.24 (br.s, 1H, amide NH), 7.71–
7.68 (d, 1H, J= 7.8 Hz, ArH), 7.57–7.54 (d, 1H,
J= 8.4 Hz, ArH), 7.36–7.31 (d, 1H, J= 7.8 Hz, ArH),
7.16–7.11 (m, 2H, ArH), 4.47–4.43 (t, 2H, J= 5.4 Hz,
NCH2CH2N) 3.99–3.95 (t, 2H, J= 6.0 Hz, NCH2CH2N),
3.77–3.74 (t, 2H, J= 4.8 Hz), 3.65–3.62 (t, 2H,
J= 4.2 Hz), 3.10 (s, 2H, amedic CH2), 3.07–3.03 (t, 2H,
J= 5.1 Hz), 2.53–2.50 (t, 2H, J= 8.7 Hz) ppm. 13C NMR
(75 MHz, DMSO-d6) d: 50.13, 53.65, 53.65, 60.64, 63.86,
63.86, 66.49, 66.49, 106.06, 111.33, 121.02, 122.61, 124.93,
127.13, 129.41, 136.74, 158.92, 168.71 ppm. LC–MS: (329.3,
97.16%).Please cite this article in press as: Toche, R.B., Janrao, R.A. Synthesis, characterizat
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(4-(cyclopropylmethyl) piperazin-1-yl)acetamide (12c)
White solid: Yield, 0.101 g, 74%; m.p. 188–190 C. 1H NMR
(300 MHz, DMSO-d6) d: 10.12 (br.s, 1H, pyrazino NH),
7.71–7.68 (d, 1H, J= 8.1 Hz, ArH), 7.57–7.54 (d, 1H,
J= 8.4 Hz, ArH), 7.36–7.31 (t, 1H, J= 7.2 Hz, ArH), 7.10–
7.14 (m, 2H, ArH), 4.44–4.41 (t, 2H, J= 5.1 Hz, NCH2CH2N),
3.96–4.00 (t, 2H, J= 6.0 Hz, NCH2CH2N), 3.08 (s, 2H,
amedic CH2), 2.43–2.69 (m, 8H, piprazine), 2.18–2.16 (d, 2H,
J= 6.6 Hz), 0.819 (m, 1H, cyclopropyl CH), 0.46–0.44 (d,
2H, J= 7.2 Hz), 0.072–0.059 (d, 2H, J= 3.9 Hz) ppm. 13C
NMR (75 MHz, DMSO-d6) d: 4.18, 4.18, 8.75, 50.12, 52.98,
52.98, 53.33, 53.33, 60.54, 63.36, 106.02, 111.33, 121.02,
122.61, 124.91, 127.14, 129.45, 136.74, 158.91, 168.87 ppm.
LC–MS: (382.3, 96.81%).
4.8.4. N-(3,4-dihydro-1-oxopyrazino[1,2-a]indol-1(2H)-yl)-2-
(dimethylamino)acetamide (12d)
White solid: Yield, 0.072 g, 70%; m.p. 201–203 C. 1H NMR
(300 MHz, DMSO-d6) d: 10.23 (br.s, 1H, pyrazino NH),
7.71–7.68 (d, 1H, J= 8.1 Hz, ArH), 7.53–7.54 (d, 1H,
J= 8.4 Hz, ArH), 7.36–7.31 (t, 1H, J= 7.1 Hz, ArH), 7.16–
7.11 (t, 2H, J= 6.9 Hz, ArH), 4.46–4.42 (t, 2H, J= 5.4 Hz,
NCH2CH2N), 3.98–3.94 (t, 2H, J= 6.0 Hz, NCH2CH2N),
3.03 (s, 2H, amedic CH2), 2.29 (s, 6H, N(CH3)2) ppm.
13C
NMR (75 MHz, DMSO-d6) d: 45.90, 45.90, 50.12, 61.80,
106.02, 111.31, 121.0, 122.60, 124.90, 127.14, 129.48, 136.73,
158.90, 169.11 ppm. LC–MS: (287.2, 99%).
5. Conclusion
The new synthesized compounds exhibited promising antibac-
terial activity against E. coli, P. aeruginosa, S. aureus, and S.
pyogenes strains, while antifungal activity against C. albicans,
A. niger, and A. clavatus strains. Compounds 4e and 12b pos-
sess excellent activity against both bacterial and fungal species.
It is observed that introduction of morpholine group signifi-
cantly enhances the microbial activity against both bacterial
and fungal species.
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